AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16001680 — intervention group
Group type: COMPARATOR
Intervention: Conventional serum tumor markers (carcinoembryonic antigen or carbohydrate antigen 19‐9)
Number of subjects: 63
Study 11450476 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 30
Study 11450476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9669003 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB
Number of subjects: 20
Study 9669003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB
Number of subjects: 20
Study 8002119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia at Low Altitude (FIO2 = 0.137 +/‐ 0.001)
Number of subjects: 25
Study 8002119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normoxia at High Altitude (FIO2 = 0.306 +/‐ 0.006)
Number of subjects: 25
Study 3400296 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapies for chronic cardiovascular diseases
Number of subjects: 1000
Study 3400296 — intervention group
Group type: EXPERIMENTAL
Intervention: Markoff-model application
Number of subjects: 1000
Study 3400296 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy-dependent susceptibility analysis
Number of subjects: 1000
Study 8396087 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 252) 500 mg once daily for three days
Number of subjects: 510
Study 8396087 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (n = 258) 250 mg twice daily for ten days
Number of subjects: 510
Study 679555 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded-compression antiembolism stockings
Number of subjects: 18
Study 679555 — intervention group
Group type: COMPARATOR
Intervention: No stockings (Control)
Number of subjects: 18
Study 31710844 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (1 ng/kg/min)
Number of subjects: 50
Study 31710844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 50
Study 31106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking more than 10,000 steps (Group C)
Number of subjects: 90
Study 31106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking 5,000-9,999 steps (Group B)
Number of subjects: 90
Study 31106548 — intervention group
Group type: COMPARATOR
Intervention: Walking less than 5,000 steps (Group A)
Number of subjects: 90
Study 28103276 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey type 1 (Kimia Company, Iran)
Number of subjects: 87
Study 28103276 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey type 2 (Shahde-Golha, Iran)
Number of subjects: 87
Study 28103276 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (DPH)
Number of subjects: 87
Study 25596108 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy to the anorectum and rectum
Number of subjects: 754
Study 25596108 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy to the anal canal
Number of subjects: 754
Study 25596108 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy to the rectum
Number of subjects: 754
Study 23656847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 142
Study 23656847 — intervention group
Group type: COMPARATOR
Intervention: Parenting education program
Number of subjects: 142
Study 21161263 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb in down position
Number of subjects: 20
Study 21161263 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb in horizontal position
Number of subjects: 20
Study 21161263 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb in up position
Number of subjects: 20
Study 20031019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid bound spermatozoa (HA(+))
Number of subjects: 44
Study 20031019 — intervention group
Group type: COMPARATOR
Intervention: Non-bound spermatozoa (HA(-))
Number of subjects: 44
Study 17185127 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 60
Study 17185127 — intervention group
Group type: EXPERIMENTAL
Intervention: K3
Number of subjects: 60
Study 17185127 — intervention group
Group type: COMPARATOR
Intervention: Hand Hedstrom files
Number of subjects: 60
Study 15504839 — intervention group
Group type: EXPERIMENTAL
Intervention: SR clarithromycin (500 mg daily)
Number of subjects: 296
Study 11241124 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded Dacron (HBD)
Number of subjects: 209
Study 11241124 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 209
Study 9582180 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10
Study 9582180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8116811 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (3 doses of 500 mg each at 4-hr intervals on the first day, followed by 500 mg a day for six days; total dose 4.5 g)
Number of subjects: 26
Study 8116811 — intervention group
Group type: COMPARATOR
Intervention: Quinine-tetracycline (Q7T7 for seven days)
Number of subjects: 26
Study 3396574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted for 36 h (A)
Number of subjects: 5
Study 3396574 — intervention group
Group type: COMPARATOR
Intervention: Postabsorptive (overnight fast, D)
Number of subjects: 5
Study 3396574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted (36 h) and refed with glucose (B)
Number of subjects: 5
Study 3396574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted (36 h) and refed with glycerol (C)
Number of subjects: 5
Study 31446787 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal cardiac function
Number of subjects: 535
Study 31446787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage A heart failure
Number of subjects: 535
Study 31446787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage B heart failure
Number of subjects: 535
Study 31446787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage C heart failure
Number of subjects: 535
Study 31446787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage D heart failure
Number of subjects: 535
Study 31446787 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated body mass index (BMI)
Number of subjects: 535
Study 30305115 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 89
Study 28973220 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the reference value
Number of subjects: 298
Study 28973220 — intervention group
Group type: COMPARATOR
Intervention: Standard management strategy of treating SBP less than 80 mm Hg or lower than 40% from the reference value
Number of subjects: 298
Study 28973220 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment group
Number of subjects: 298
Study 28973220 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 298
Study 26535969 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release hydrocodone (20-300mg) every 12 hours
Number of subjects: 391
Study 23427068 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty (VP)
Number of subjects: 57
Study 20673731 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction, rigid internal fixation, and functional treatment
Number of subjects: 21
Study 20673731 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and functional treatment
Number of subjects: 21
Study 20673731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 19059362 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 5
Study 17106197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg once a day, increased to 100 mg twice a day after 10 days if tolerated)
Number of subjects: 80
Study 17106197 — intervention group
Group type: COMPARATOR
Intervention: Control (without thalidomide)
Number of subjects: 80
Study 17106197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 80
Study 17106197 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 17106197 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide and Control
Number of subjects: 80
Study 14739814 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral anesthesia with continuous paravertebral postoperative analgesia using levobupivacaine
Number of subjects: 20
Study 14739814 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine analgesia
Number of subjects: 20
Study 14739814 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral anesthesia
Number of subjects: 20
Study 11474348 — intervention group
Group type: EXPERIMENTAL
Intervention: Proceed, a gelatin‐based hemostatic sealant
Number of subjects: 127
Study 11474348 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam‐thrombin
Number of subjects: 127
Study 9725293 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging
Number of subjects: 0
Study 9725293 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced MR imaging
Number of subjects: 0
Study 9725293 — intervention group
Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 0
Study 8112185 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg miglitol 3 times a day
Number of subjects: 192
Study 8112185 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg miglitol 3 times a day
Number of subjects: 192
Study 8112185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 3180305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 2g iv every 12 hours
Number of subjects: 60
Study 3180305 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin (150mg iv every 12 hours) plus Clindamycin (600mg iv every 8 hours)
Number of subjects: 60
Study 3180305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 60
Study 3180305 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin plus Clindamycin
Number of subjects: 60
Study 30353612 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit 'Children-What does it involve?' and Real-Care-Baby simulator
Number of subjects: 6
Study 28808771 — intervention group
Group type: COMPARATOR
Intervention: Classical treatment (antibiotics, anti-inflammatories and low-fibre diet)
Number of subjects: 0
Study 28808771 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (anti-inflammatories and low-fibre diet)
Number of subjects: 0
Study 27656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily for four months
Number of subjects: 379
Study 27656713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 27656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 379
Study 27656713 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 379
Study 23333003 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored arm (Etco2 monitoring)
Number of subjects: 50
Study 23333003 — intervention group
Group type: COMPARATOR
Intervention: Control arm (clinical assessment)
Number of subjects: 50
Study 21675061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 21675061 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 19701035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 126
Study 19701035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 16400055 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (30% protein, 40% carbohydrate, 30% fat)
Number of subjects: 12
Study 16400055 — intervention group
Group type: COMPARATOR
Intervention: Adequate-Protein (AP) diet (10% protein, 60% carbohydrate, 30% fat)
Number of subjects: 12
Study 14767999 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care and hypertonic saline (30%) infusion to maintain serum sodium levels of 145‐155 mmol/L (Group 2)
Number of subjects: 30
Study 14767999 — intervention group
Group type: COMPARATOR
Intervention: Normal standard of care (Group 1)
Number of subjects: 30
Study 11416710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 51
Study 9296466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin sodium, Fragmin)
Number of subjects: 1506
Study 8095362 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100
Study 8095362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 100
Study 8095362 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 100
Study 8095362 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with haloperidol, chlorpromazine, and perphenazine
Number of subjects: 100
Study 3100676 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior dental anaesthesia via the direct intraoral approach
Number of subjects: 90
Study 3100676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular conduction anaesthesia via extraoral landmarks (Gow‐Gates)
Number of subjects: 90
Study 3100676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular conduction anaesthesia via the tuberosity approach (Akinosi)
Number of subjects: 90
Study 31234104 — intervention group
Group type: EXPERIMENTAL
Intervention: Static air support surfaces
Number of subjects: 308
Study 31234104 — intervention group
Group type: COMPARATOR
Intervention: Alternating air pressure support surfaces
Number of subjects: 308
Study 29764602 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorders assessment through face-to-face interview using CIDI v2.1
Number of subjects: 250
Study 29764602 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service utilization for mental problems
Number of subjects: 250
Study 29764602 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally adequate treatment for psychiatric disorders
Number of subjects: 250
Study 25675385 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%) infusion
Number of subjects: 12
Study 25675385 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF‐α (1000 ng/m(2) · h) infusion
Number of subjects: 12
Study 24325959 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI) measuring global systolic function (s') and global diastolic function (e')
Number of subjects: 391
Study 24325959 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI) measuring both global systolic function (s') and global diastolic function (e')
Number of subjects: 391
Study 22786601 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough Series implementation program
Number of subjects: 1657
Study 22786601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1657
Study 19183162 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 108
Study 19183162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 19183162 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 108
Study 19183162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 108
Study 19183162 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 108
Study 17944658 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients on ART
Number of subjects: 16
Study 17944658 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study 15887898 — intervention group
Group type: EXPERIMENTAL
Intervention: RWU (reference warm up based on FWU)
Number of subjects: 9
Study 15887898 — intervention group
Group type: EXPERIMENTAL
Intervention: RWU‐10 (warm up intensity diminished by 10% compared to RWU)
Number of subjects: 9
Study 15887898 — intervention group
Group type: EXPERIMENTAL
Intervention: RWU+10 (warm up intensity increased by 10% compared to RWU)
Number of subjects: 9
Study 15887898 — intervention group
Group type: COMPARATOR
Intervention: NWU (no warm up)
Number of subjects: 9
Study 12643380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural tent procedure (group 1)
Number of subjects: 200
Study 9884132 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.2 g/kg
Number of subjects: 49
Study 9884132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.4 g/kg
Number of subjects: 49
Study 9884132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg
Number of subjects: 49
Study 7614105 — intervention group
Group type: EXPERIMENTAL
Intervention: Industrial labourers
Number of subjects: 947
Study 7614105 — intervention group
Group type: COMPARATOR
Intervention: Nomads
Number of subjects: 947
Study 1513972 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy using portable liquid oxygen systems
Number of subjects: 0
Study 1513972 — intervention group
Group type: COMPARATOR
Intervention: No treatment by oxygen
Number of subjects: 0
Study 6388253 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 26
Study 6388253 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 26
Study 6388253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30706471 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 306
Study 30706471 — intervention group
Group type: COMPARATOR
Intervention: Cu‐IUD
Number of subjects: 306
Study 29324864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine with artemether-lumefantrine (AL)
Number of subjects: 90
Study 29324864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg primaquine with artemether-lumefantrine (AL)
Number of subjects: 90
Study 29324864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine with dihydroartemisinin-piperaquine (DP)
Number of subjects: 90
Study 29324864 — intervention group
Group type: COMPARATOR
Intervention: AL plus 0.25 mg/kg primaquine (G6PD-normal)
Number of subjects: 90
Study 29324864 — intervention group
Group type: COMPARATOR
Intervention: AL plus 0.40 mg/kg primaquine (G6PD-normal)
Number of subjects: 90
Study 27126076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 73
Study 27126076 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (ET)
Number of subjects: 73
Study 27126076 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 73
Study 24186565 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 46
Study 24186565 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 22417813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Number of subjects: 539
Study 22417813 — intervention group
Group type: COMPARATOR
Intervention: Generic Information (GI)
Number of subjects: 539
Study 21109086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal packing during nasal surgery
Number of subjects: 100
Study 21109086 — intervention group
Group type: COMPARATOR
Intervention: No pharyngeal packing during nasal surgery
Number of subjects: 100
Study 18248393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid supplementation for 2 months
Number of subjects: 16
Study 18248393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15781541 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg clonidine
Number of subjects: 41
Study 15781541 — intervention group
Group type: COMPARATOR
Intervention: 2 mL saline (placebo)
Number of subjects: 41
Study 12559267 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mL of 0.2% oxybuprocaine hydrochloride gel
Number of subjects: 133
Study 12559267 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mL of plain lubricating gel
Number of subjects: 133
Study 12559267 — intervention group
Group type: COMPARATOR
Intervention: No gel injection
Number of subjects: 133
Study 10342416 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 10342416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 0
Study 10342416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0
Study 10342416 — intervention group
Group type: EXPERIMENTAL
Intervention: All three opioids (morphine, pethidine, fentanyl)
Number of subjects: 0
Study 10342416 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing opioids
Number of subjects: 0
Study 7924357 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual changes (shift from above to below water)
Number of subjects: 0
Study 7924357 — intervention group
Group type: COMPARATOR
Intervention: Same test of visual recognition
Number of subjects: 0
Study 2681675 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (CHx) used twice daily for 6 weeks
Number of subjects: 40
Study 2681675 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (CHx)
Number of subjects: 40
Study 2681675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 142845 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 125
Study 142845 — intervention group
Group type: EXPERIMENTAL
Intervention: streptozotocin
Number of subjects: 125
Study 142845 — intervention group
Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 125
Study 30257588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg methylergometrine per os twice a day for 10 days
Number of subjects: 220
Study 30257588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 31419272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 16
Study 31419272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28368311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 40
Study 28368311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 40
Study 26409403 — intervention group
Group type: EXPERIMENTAL
Intervention: Real repetitive sacral root magnetic stimulation (rSMS; 15 Hz with a total of 1500 pulses/session) for 10 sessions
Number of subjects: 44